Navigation Links
Optimer Reports Second Quarter 2013 Financial Results
Date:8/1/2013

JERSEY CITY, N.J., Aug. 1, 2013 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today unaudited financial results for the second quarter ended June 30, 2013.  

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

Financial Highlights

  • Second quarter 2013 DIFICID net product sales in the U.S. and Canada of $19.0 million, compared to $15.2 million in the corresponding quarter in 2012, and up 13% from $16.8 million in the first quarter
  • Second quarter 2013 total net revenues of $20.1 million
  • Cash, cash equivalents and short-term investments at June 30, 2013 totaled $77.5 million
  • 2013 net loss for the second quarter was $26.9 million, or $0.55 per share
  • Financial Overview
    Total net revenues for the quarters ended June 30, 2013 and 2012 were $20.1 million and $49.8 million, respectively, a decrease of $29.7 million.  The year-ago period included $32.4 million in up-front and milestone payments under our collaboration and license agreements with Astellas Japan and Astellas Pharma Europe.

    DIFICID net product sales for the quarters ended June 30, 2013 and 2012 were $19.0 million and $15.2 million, respectively, an increase of $3.8 million, or 25%.  The increase was due to an increase in the number of customers ordering DIFICID and increased sales to existing DIFICID customers, as well as the impact of a price increase. We recognize product sales of DIFICID upon delivery of product to our wholesalers.

    Contract revenues for the quarters ended June 30, 2013 and 2012 were $1.1 million and $34.5 million.  Contract revenue in the quarter ended June 30, 2013 was related to product shipments to our collaborative partners and royalties from Astellas Pharma Europe.
    '/>"/>

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2013 Financial Results
    2. Todays Research: Inovio Pharma, Sequenom, Peregrine Pharma, Onyx Pharma, and Optimer Pharma
    3. Optimer Pharmaceuticals Appoints Eric Sirota as Chief Operating Officer
    4. Optimer Reports First Quarter 2013 Financial Results
    5. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2013 Financial Results
    6. Optimer Reports Fourth Quarter and Fiscal Year 2012 Financial Results
    7. Optimer Pharmaceuticals Board of Directors Appoints Board Chairman, Dr. Henry McKinnell, Chief Executive Officer
    8. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Fiscal Year 2012 Financial Results
    9. Optimer Pharmaceuticals to Present at Leerink Swann Global Healthcare Conference
    10. Optimer Pharmaceuticals to Present at 23rd Annual Oppenheimer Healthcare Conference
    11. Optimer Pharmaceuticals to Present at November 2012 Investor Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2015)... According to a new market ... Computed Radiography, Ultrasound, Computed & Optical Coherence Tomography, MRI, ... Cardiology, Neurology) - Global Forecast to 2020", the Global ... Billion by 2020 growing at a CAGR of 6.6% ... owse 240 Tables and 44 F igures spread ...
    (Date:9/2/2015)... Md. , Sept. 2, 2015  RegeneRx ... a clinical-stage drug development company focused on tissue ... J.J. Finkelstein , President and Chief Executive Officer, ... & Renshaw Global Investment Conference, sponsored by ... be held September 8-10, 2015 at the St. ...
    (Date:9/2/2015)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and ... into a definitive agreement under which Valeant will acquire ... SURG ) for $6.50 per share in cash. In ... receive additional cash payments of up to $1.00 per ... closing.  The transaction is expected to close in the ...
    Breaking Medicine Technology:Veterinary Imaging Market Worth USD 2.8 Billion by 2020 2Veterinary Imaging Market Worth USD 2.8 Billion by 2020 3Veterinary Imaging Market Worth USD 2.8 Billion by 2020 4Veterinary Imaging Market Worth USD 2.8 Billion by 2020 5RegeneRx to Present at Rodman & Renshaw Global Investment Conference 2RegeneRx to Present at Rodman & Renshaw Global Investment Conference 3Valeant Pharmaceuticals To Acquire Synergetics USA 2Valeant Pharmaceuticals To Acquire Synergetics USA 3Valeant Pharmaceuticals To Acquire Synergetics USA 4Valeant Pharmaceuticals To Acquire Synergetics USA 5
    ... Tim Wentworth, group president for employer and key ... MHS ), is scheduled to present at the Lazard ... 17, 2010 in New York. (Logo: http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO) ... The St. Regis Hotel is scheduled to begin at ...
    ... Despite national guidelines recommending that inhaled corticosteroid (ICS) ... with mild persistent asthma, a new study finds that ... drugs that combine an ICS and a long-acting beta ... noted based on pharmacy and medical claims. The analysis ...
    Cached Medicine Technology:Medco to Present at the Lazard Capital Markets 7th Annual Healthcare Conference 2New Study: Overuse of Combination Drug Therapy in Patients with Mild Asthma Leads to Increased Costs 2New Study: Overuse of Combination Drug Therapy in Patients with Mild Asthma Leads to Increased Costs 3New Study: Overuse of Combination Drug Therapy in Patients with Mild Asthma Leads to Increased Costs 4
    (Date:9/2/2015)... ... September 02, 2015 , ... ... in the news recently following a decision by the Centers for Medicare & ... likely to average approximately $71,000 or roughly 40% of its headline-grabbing $178,000 price ...
    (Date:9/2/2015)... ... 02, 2015 , ... Date and time: Oct. 3, 2015, 9 a.m. to ... Tomlinson Road, Bryn Athyn, Pa 19009 , Cost: $50 per person; includes lunch , ... Times best-selling author Sam Keen based on his new book which he co-authored with ...
    (Date:9/2/2015)... CA (PRWEB) , ... September 02, 2015 , ... In ... featured by the Huffington Post on August 25th, writer Akela Stanfield detailed her lifelong ... While the author acknowledged that she had always seen herself as someone who would ...
    (Date:9/2/2015)... ... September 02, 2015 , ... ... endpoint data collection, cloud analytics and workflow solutions today announced the September ... pharmaceutical researchers to participate in interactive programs in which ERT scientists and ...
    (Date:9/2/2015)... , ... September 02, 2015 , ... ... healthcare industry announced today the launch of its enhanced, cloud-based mobile ePrescribing application. ... look” and focus on improving prescriber usability. A leader in health technology, RxNT ...
    Breaking Medicine News(10 mins):Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4Health News:justCommunity, Inc. and Bryn Athyn Men’s Groups Present Workshop on Family Reconciliation 2Health News:Recent Editorial on Bariatric Surgery Acceptance Illuminates a Typical Journey Towards Weight Loss Surgery, Notes Dr. Michael Feiz 2Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 2Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 3Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2
    ... New analyses from the Women,s Health Initiative (WHI) confirm that ... healthy postmenopausal women. Researchers report a trend toward an ... of hormone therapy among women who began therapy within 10 ... among women who began hormone therapy more than 10 years ...
    ... disease activity when added to interferon beta , TUESDAY, ... to standard treatment with interferon beta may reduce multiple ... new study reports. , Previous non-randomized studies found that ... disease activity. , This new phase 2 study ...
    ... ... 2010 , ... February 16, 2010 -- Aberdeen Group, a Harte-Hanks Company has released a new benchmark ... Telecom Expense Management (TEM) solutions as a strategic foundation and precursor for other ...
    ... ... all natural food service company manages to grow sales and reduce its ... second year in a row, Service Foods, the largest Home Food service ... after increasing sales. Verus Carbon Neutral once again measured and offset 100% ...
    ... ... Texas, has contracted with Atlanta-based Premier Anesthesia to manage the anesthesia services for its ... ... hospital in east Texas, has contracted with Atlanta-based Premier Anesthesia to manage the anesthesia ...
    ... ABBOTT PARK, Ill., Feb. 16 Abbott (NYSE: ... EUR 4.5 billion ( $6.2 billion ) acquisition of ... portfolio of pharmaceutical products and expanding Abbott,s presence in key global ... Abbott expects the acquisition to add approximately $2.9 billion ...
    Cached Medicine News:Health News:WHI data confirm short-term heart disease risks of combination menopausal hormone therapy 2Health News:WHI data confirm short-term heart disease risks of combination menopausal hormone therapy 3Health News:WHI data confirm short-term heart disease risks of combination menopausal hormone therapy 4Health News:Added Drug Aids MS Treatment 2Health News:AnchorPoint Sponsored Aberdeen Group Report Addresses Telecom Lifecycle Management 2Health News:AnchorPoint Sponsored Aberdeen Group Report Addresses Telecom Lifecycle Management 3Health News:AnchorPoint Sponsored Aberdeen Group Report Addresses Telecom Lifecycle Management 4Health News:AnchorPoint Sponsored Aberdeen Group Report Addresses Telecom Lifecycle Management 5Health News:Service Foods Reduces its Carbon Footprint and Grows Sales 2Health News:Service Foods Reduces its Carbon Footprint and Grows Sales 3Health News:Premier Anesthesia Forges New Partnership with Texas Hospital 2Health News:Abbott Completes Acquisition of Solvay Pharmaceuticals 2Health News:Abbott Completes Acquisition of Solvay Pharmaceuticals 3
    Cer-Met series II system....
    The Ceracup has a standard profile plastic component with a ceramic insert and the benefit of alumina-alumina contact....
    S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
    S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
    Medicine Products: